YAVNE, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that three presentations highlighting the positive results achieved by clinicians using NexoBrid® treatment as an effective enzymatic debridement for severe burns will be presented at the upcoming American Burn Association 47th Annual Meeting taking place from April 21-24, 2015 at the Hilton Chicago Hotel.
|
Title: |
"Early enzymatic debridement of deep dermal burns – first results in hands and preliminary results in face and lower extremity" |
|
Authors: |
A. Schulz, MD, University of Witten/Herdecke, Clinic for Plastic Surgery, Hand Surgery, Burn Care Center, Cologne-Merheim Medical Center, Germany |
|
Date/Time: |
April 23rd from 12:30 p.m. – 1:30 p.m. |
|
|
|
|
Title: |
"First post clinical trial experience with a commercially available enzymatic Bromelain based burn wound debridement" |
|
Authors: |
O. H. Rennekampff, MD, RWTH University, Aachen, Germany |
|
Date/Time: |
April 23rd from 12:30 p.m. – 1:30 p.m. |
|
|
|
|
Title: |
"Axillary plexus block for enzymatic debridement of partial and full thickness burns involving forearms and hands – a different way of appropriate pain management?" |
|
Authors: |
J. Horter, MD, Department of Hand, Plastic and Reconstructive Surgery-Burn Center BG Trauma Center, Ludwigshafen, Germany |
|
Date/Time: |
April 23rd from 12:30 p.m. – 1:30 p.m. |
"We are delighted to have burn specialists from Germany sharing their hands-on experience with NexoBrid at the American Burn Association Annual Meeting, following NexoBrid's initial commercial launch in Europe. A growing number of physicians are treating more and more patients with NexoBrid throughout Europe as the launch expands to other countries. We are confident that the accumulating experience of burn specialists from additional European countries will continue to be shared at future conferences this year, contributing to the further advancement of burn care," said Gal Cohen, President and Chief Executive Officer of MediWound.
About the American Burn Association
The American Burn Association and its members dedicate their efforts and resources to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. The ABA has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers. The ABA's multidisciplinary membership enhances its ability to work toward common goals with other organizations on educational programs.
About NexoBrid
NexoBrid is an easy-to-use, topically-applied pharmaceutical product that removes dead or damaged tissue, known as eschar, in four hours without harming the surrounding healthy tissues. NexoBrid was granted marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, and was initially launched in Europe and Israel in 2014. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or "debridement" is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard-of-care (SOC), burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns and has been launched in Europe and Israel. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
CONTACT: Sharon Malka
Chief Financial & Operation Officer
MediWound Ltd.
ir@mediwound.co.il
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
